Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II randomised, double blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of CT327 topical ointment (0.05% and 0.5% w/w) compared to vehicle, in subjects with mild or moderate atopic dermatitis with at least moderate pruritus

Next Previous
X
Search
Trial Profile

A phase II randomised, double blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of CT327 topical ointment (0.05% and 0.5% w/w) compared to vehicle, in subjects with mild or moderate atopic dermatitis with at least moderate pruritus

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegcantratinib (Primary)
  • Indications Atopic dermatitis; Pruritus
  • Focus Therapeutic Use
  • Sponsors Creabilis SA

    • Most Recent Events

    • 19 Mar 2015 Results published in Acta Dermato-Venereologica, according to a Creabilis media release.
    • 17 Oct 2013 New trial record
    • 18 Sep 2013 The first patients have been treated, according to a Creabilis SA media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top